PMID- 32014687
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 125
DP  - 2020 May
TI  - Overexpression of circRNA_100290 promotes the progression of laryngeal squamous 
      cell carcinoma through the miR-136-5p/RAP2C axis.
PG  - 109874
LID - S0753-3322(20)30064-0 [pii]
LID - 10.1016/j.biopha.2020.109874 [doi]
AB  - Circular RNAs (circRNAs) exert critical functions in tumorigenesis and tumor 
      development, but whether and how circRNAs contribute to laryngeal squamous cell 
      carcinoma (LSCC) is unclear. In this study, we explored the function and 
      mechanisms of circRNA_100290 in LSCC. Tissue samples were obtained from 40 
      patients with LSCC. The expression of circRNA_100290 and other targets was 
      measured through quantitative reverse transcription-polymerase chain reaction and 
      western blot analysis. Cell proliferation, colony-forming ability, and apoptosis 
      were tested using CCK-8 assay and EdU assay, colony formation assay, and flow 
      cytometry, respectively. Cell migration and invasion were detected by Transwell 
      assay. Moreover, the interactions between circRNA_100290, miR-136-5p, and RAP2C 
      were analyzed by bioinformatics, and verified by dual-luciferase reporter assays. 
      Here, we found that circRNA_100290 expression was significantly upregulated in 
      LSCC tissues and cell lines compared with the normal controls. Expression of 
      circRNA_100290 positively correlated with advanced TNM stage and lymph node 
      metastasis in LSCC patients. In cell culture, upregulation of circRNA_100290 
      promoted LSCC cell proliferation, migration, and invasion, while it inhibited 
      cell apoptosis; downregulating circRNA_100290 exerted the opposite effects. In 
      vivo, circRNA_100290 overexpression dramatically promoted tumor growth. 
      Mechanistically, circRNA_100290 may act as a sponge of miR-136-5p, and inhibiting 
      miR-136-5p in LSCC cells indeed reversed the effects of circRNA_100290 
      downregulation. The RAS oncogene RAP2C was predicted to be a target of 
      miR-136-5p, and downregulating RAP2C in LSCC cells partially reversed the 
      oncogenic effects of circRNA_100290 overexpression or miR-136-5p decrease. Our 
      findings suggest that circRNA_100290 promotes LSCC progression by targeting the 
      miR-136-5p/RAP2C axis, which may lead to the identification of potential 
      therapeutic targets.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Wang, Zhenxiao
AU  - Wang Z
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Friendship Hospital, 
      Capital Medical University, 100050, Beijing, China. Electronic address: 
      zhenxiao_wang@ccmu.edu.cn.
FAU - Huang, Chaoping
AU  - Huang C
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Friendship Hospital, 
      Capital Medical University, 100050, Beijing, China. Electronic address: 
      caogua2008@sina.com.
FAU - Zhang, Aobo
AU  - Zhang A
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Friendship Hospital, 
      Capital Medical University, 100050, Beijing, China. Electronic address: 
      geniusbo@163.com.
FAU - Lu, Cheng
AU  - Lu C
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Friendship Hospital, 
      Capital Medical University, 100050, Beijing, China. Electronic address: 
      lucheng2@126.com.
FAU - Liu, Liangfa
AU  - Liu L
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Friendship Hospital, 
      Capital Medical University, 100050, Beijing, China. Electronic address: 
      liuliangfa1@126.com.
LA  - eng
PT  - Journal Article
DEP - 20200131
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (MIRN136 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Circular)
RN  - EC 3.6.1.- (Rap2C protein, human)
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Apoptosis
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - Male
MH  - Mice
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Promoter Regions, Genetic
MH  - *RNA Interference
MH  - RNA, Circular/*genetics
MH  - Xenograft Model Antitumor Assays
MH  - ras Proteins/*genetics
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - RAP2C
OT  - circRNA_100290
OT  - miR-136-5p
COIS- Declaration of Competing Interest The authors declare that there are no conflicts 
      of interest.
EDAT- 2020/02/06 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/02/05 06:00
PHST- 2019/10/29 00:00 [received]
PHST- 2020/01/06 00:00 [revised]
PHST- 2020/01/10 00:00 [accepted]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/02/05 06:00 [entrez]
AID - S0753-3322(20)30064-0 [pii]
AID - 10.1016/j.biopha.2020.109874 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2020 May;125:109874. doi: 10.1016/j.biopha.2020.109874. Epub 
      2020 Jan 31.